Ascendis Pharma ASASND -0.24%37 PE Ratio (TTM) is 30.65 as of Jun. 29, 2026, which is 13% above its 10-year median of 27.04. GuruFocus rates ASND with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 273 Biotechnology companies, Ascendis Pharma AS ranks worse than 58.61% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-06-29), Ascendis Pharma AS's share price is
$260.75.
Ascendis Pharma AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $8.51. Therefore, Ascendis Pharma AS's PE Ratio (TTM) for today is 30.65.
The historical rank and industry rank for Ascendis Pharma AS's PE Ratio (TTM) or its related term are showing as below:
ASND'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 24.74 Med: 27.04 Max: 30.65
Current: 30.65
During the past 13 years, the highest PE Ratio (TTM) of Ascendis Pharma AS was 30.65. The lowest was 24.74. And the median was 27.04.
ASND's PE Ratio (TTM) is ranked worse than 58.61% of 273
companies
in the Biotechnology industry
Industry Median: 25.91
vs ASND: 30.65
During the past 3 years, the average EPS without NRIGrowth Rate was 31.40% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 14.00% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was -11.20% per year.
During the past 13 years, Ascendis Pharma AS's highest 3-Year average EPS without NRI Growth Rate was 31.40% per year. The lowest was -68.10% per year. And the median was -28.30% per year.
Ascendis Pharma AS's EPS (Basic) for the
three
months ended in Mar. 2026 was $11.79.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $9.24.
Ascendis Pharma AS (NAS:ASND) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Ascendis Pharma AS PE Ratio (TTM) Related Terms
Ascendis Pharma AS PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for Ascendis Pharma AS's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASND vs JAZZ, BBIO, EXEL: PE Ratio (TTM) Comparison
For the Biotechnology subindustry, Ascendis Pharma AS's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascendis Pharma AS PE Ratio (TTM) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Ascendis Pharma AS's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Ascendis Pharma AS's Share Price of today is $260.75.
Ascendis Pharma AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.51.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Ascendis Pharma AS (ASND) has a PE Ratio (TTM) of 30.65 as of Jun. 29, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Ascendis Pharma AS and its competitors. This is 13% above median its historical median of 27.04. Over the past decade, Ascendis Pharma AS's PE Ratio (TTM) has ranged from 24.74 to 30.65. According to the industry distribution chart, Ascendis Pharma AS ranks #160 out of 273 companies in the Biotechnology industry, placing it in the top 58.6%.
Is Ascendis Pharma AS's PE Ratio (TTM) too high?
Ascendis Pharma AS's current PE Ratio (TTM) of 30.65 is 13% above median its 10-year median of 27.04. Over the past 10 years, this metric has ranged from a low of 24.74 to a high of 30.65. The Biotechnology industry median PE Ratio (TTM) is 25.91. Ascendis Pharma AS's value of 30.65 is 18.3% above this industry median. Based on the distribution chart, Ascendis Pharma AS ranks #160 out of 273 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's PE Ratio (TTM) compare to JAZZ and BBIO?
According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #160 out of 273 companies for PE Ratio (TTM). This places Ascendis Pharma AS in the lower half of its industry. The industry median PE Ratio (TTM) is 25.91. Ascendis Pharma AS's value of 30.65 is 18.3% above this benchmark. Historically, Ascendis Pharma AS's own PE Ratio (TTM) has ranged from 24.74 to 30.65 over the past decade. While the company's 10-year median is 27.04 vs. the industry median of 25.91, Ascendis Pharma AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Biotechnology company?
The median PE Ratio (TTM) among Biotechnology companies is 25.91, based on 273 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascendis Pharma AS's current PE Ratio (TTM) of 30.65 is 18.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Ascendis Pharma AS and its competitors. For the Biotechnology industry, the median PE Ratio (TTM) is 25.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascendis Pharma AS's current PE Ratio (TTM) is 30.65, which is 13% above median its own 10-year median of 27.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (ASND) has a current PE Ratio (TTM) of 30.65. The current PE Ratio (TTM) is 30.65, which is 13% above median its 10-year median of 27.04 and 18.3% above the Biotechnology industry median of 25.91. Ascendis Pharma AS's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Ascendis Pharma AS (ASND), the current PE Ratio (TTM) is 30.65 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score
Get the complete analysis for ASND
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASND has been successfully added to your 
